cas 145040-37-5, Candesartan cilexetil | Articles data

Articles about 145040-37-5Total 41 be found

Article title
Article abstract
Author
Journal number and time
Download

Preparation method of candesartan cilexetil
The invention relates to a preparation method of candesartan cilexetil. The preparation method comprises the following steps: dissolving triphenylmethyl candesartan cilexetil in an alcohol solvent, adding a sulfuric acid-methanol solution at low temperature, adding halogenated hydrocarbon into a reaction solution after the reaction is finished, regulating the pH value of the reaction solution by using an aqueous alkaline solution, separating an organic layer, and conducting concentrating; and adding acetone into a concentrate obtained in the previous step, adding water, and conducting crystallizing; According to the method, reaction conditions and post-treatment conditions are optimized, operation is simplified, impurities can be effectively removed, and the method is low in cost, safe tooperate and suitable for industrial production.
-
Paragraph 0021-0023

(2020/11/23)

Candesartan cilexetil intermediate and application thereof
The invention provides a candesartan cilexetil intermediate and a preparation method thereof. The intermediate is synthesized through the following route. The intermediate is synthesized, so that theformation of many byproducts in the reduction step in the prior art is effectively avoided, oxalic acid salifying crystallization is adopted for diamine purification in the subsequent step of synthesizing candesartan cilexetil through the intermediate, and a high-quality candesartan cilexetil bulk drug can be obtained.
-
(2020/10/20)

Preparation method of candesartan cilexetil and intermediate of candesartan cilexetil
The invention relates to a preparation method of candesartan cilexetil and an intermediate of the candesartan cilexetil. The intermediate is hydrogenated to remove benzyloxycarbonyl and triphenylmethyl protecting groups in the presence of Pd/C, and nitro is reduced to amino, so that the 'one-pot multi-step' operation is realized, no acid is needed during deprotection, side-chain cyclohexyl carbonate degradation is avoided, the product purity is high, and the candesartan cilexetil is prepared by cyclization. According to the preparation method of candesartan cilexetil and the intermediate of the candesartan cilexetil disclosed by the invention, the problems in the prior art that side chains are degraded when common t-butyloxycarboryl protecting groups on amino are removed under strong acidconditions and triphenylmethyl protecting groups on tetrazole are transferred to amino are solved.
-
Paragraph 0026; 0028; 0030

(2019/08/01)

A method for preparing ester
The invention provides a preparation method of candesartan cilexetil. The preparation method comprises steps I-IV. The step I concretely comprises the following substeps of adding candesartan and dichloromethane in a reaction container; slowly and dropwise adding triethylamine at the temperature of 10-15 DEG C; raising the temperature of a reaction system to 21-25 DEG C after dropwise adding of the triethylamine is fnished; adding triphenylchloromethane in batches; reacting for 3-4 hours; adding 0.1 mol/L HCl at one step after reaction is complete and adjusting pH (potential of hydrogen) to be 5-6; then slowly and dropwise adding 9 mol/L HCl and adjusting pH to be 2-3; leaving standstill; separating a water layer and an organic layer; adding saturated salt water in the organic layer to wash the organic layer; leaving standstill to achieve a layering effect; separating out the organic layer; performing decompress concentration on the organic layer to remove the dichloromethane; adding absolute ethyl alcohol in residual viscous substances; raising temperature to 45-50 DEG C; stirring for 3 hours; stopping heating after a large amount of white solids are separated out; reducing to room temperature; performing suction filtration; washing filter cakes with ethyl alcohol; and drying to obtain trityl candesartan.
-
Paragraph 0006; 0068; 0084; 0098

(2018/05/24)

METHOD FOR PRODUCING DETRITYLATED PRODUCT
PROBLEM TO BE SOLVED: To provide a method for efficiently producing a sartan-based drug substance such as losartan, valsartan, olmesartan medoxomil, irbesartan, candesartan cilexetil, by performing detritylation of a trityl group-containing compound under a mild condition. SOLUTION: The present invention provides a method for producing a detritylated product by bringing a trityl group-containing compound represented by a formula (1) into contact with a compound containing iron trichloride (R is an organic group; Ph is a phenyl group). SELECTED DRAWING: None COPYRIGHT: (C)2019,JPOandINPIT
-
Paragraph 0090-0094

(2019/02/27)

A trityl protecting group by removing method of preparing losartan medicine
The invention discloses a method for preparation of a Sartan drug by removal of a triphenylmethyl protective group. The method includes: under the catalysis of an insoluble weak acid, subjecting a Sartan prodrug and methanol to deprotection reaction, and after complete reaction, conducting aftertreatment to obtain the Sartan drug. The method has the characteristics of low cost, few side product, high quality product, and simple aftertreatment. At the same time, montmorillonite can be taken as insoluble weak acid, and the cost is low, thus being convenient for industrial production.
-
Paragraph 0032-0039; 0044

(2018/07/30)

DEPROTECTION METHOD FOR TETRAZOLE COMPOUND
The present invention relates to a method of deprotecting a tetrazole compound, useful as an intermediate for angiotensin II receptor blockers, and provides a novel production method of angiotensin II receptor blockers. Provided is a production method of a compound represented by the formula [3] or [4] or a salt thereof, including (i) reducing a compound represented by the formula [1] or [2] or a salt thereof in the presence of a metal catalyst and an alkaline earth metal salt, or (ii) reacting the compound with a particular amount of Br?nsted acid: wherein each symbol is as defined in the present specification.
-
(2015/09/23)

A NEW PROCESS FOR THE PREPARATION OF CANDESARTAN CILEXETIL
The present invention discloses the process for the preparation of candesartan cilexetil comprising the steps of hydrogenation of N02group of 1-(((cyclohexyloxy)carbonyl)oxy)ethyl 2-((tert-butoxycarbonyl)((2'-(1-tntyl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)amino)-3-nitrobenzoate by using a catalyst in an organic solvent, subsequent cleavage of the N-Boc group under acidic condition, followed by isolation of solid 1-(((cyclohexyloxy)carbonyl) oxy)ethyl 2-(((2'-(l H-tetrazol-5-yl)-[1,1'-bipheny|]-4-yl)methyl)amino)-3-aminobenzoate in the form of any pharmaceutically acceptable salt and ring closure by using tetraethyl orthocarbonate in an organic solvent to obtain the final product candesartan cilexetil.
-
(2015/07/07)

COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING SALT SENSITIVITY OF BLOOD PRESSURE
To characterize the urinary exosome miRNome, microarrays were used to identify the miRNA spectrum present within urinary exosomes from ten individuals that were previously classified for their salt sensitivity status. The present application discloses distinct patterns of selected exosomal miRNA expression that were different between salt-sensitive (SS), salt-resistant (SR), and inverse salt-sensitive (ISS) individuals. These miRNAs can be useful as biomarkers either individually or as panels comprising multiple miRNAs. The present invention provides compositions and methods for identifying, diagnosing, monitoring, and treating subjects with salt sensitivity of blood pressure. The applications discloses panels of miRNAs useful for comparing profiles, and in some cases one or more of the miRNAs in a panel can be used. The miRNAs useful for distinguishing SS and SR or ISS and SR subjects. One or more of the 45 miRNAs can be used. Some of the miRNAs have not been previously reported to be circulating. See those miRNAs with asterisks in FIG. 1 and below. The present invention encompasses the use of one or more of these markers for identifying and diagnosing SR, SS, and ISS subjects.
-
(2015/02/05)

Efficient catalytic system for Ru-catalyzed C-H arylation and application to a practical synthesis of a pharmaceutical
A series of K salts of sulfonic acids have been tested as a cocatalyst for Ru-catalyzed C-H arylation. Among them, K 2, 4, 6-trimethylbenzenesulfonate (TMBSK) was found to be most active, and generality of the reaction was confirmed for a variety of nitrogen-containing heterocycles to give corresponding functionalized biaryls in high yields. The present methodology was applied to a practical synthesis of Candesartan Cilexetil.
Seki, Masahiko
p. 4047 - 4050
(2015/02/19)

Novel and efficient debenzylation of N-benzyltetrazole derivatives with the rosenmund catalyst
The Rosenmund catalyst (Pd/BaSO4) was found to efficiently catalyze debenzylation of N-benzyltetrazole derivatives with ammonium formate by catalytic transfer hydrogenation under mild conditions. The protocol has been applied to functionalized substrates to provide various angiotensin II receptor blockers in excellent yields.
Seki, Masahiko
p. 3249 - 3255
(2015/01/08)

PROCESS FOR PRODUCTION OF BIPHENYL DERIVATIVE
The invention provides a production method of a biaryltetrazole derivative useful as an intermediate for an angiotensin II receptor antagonist. The method comprises reacting an aryltetrazole derivative with a benzene derivative, deprotecting or reducing the resulting compound, and halogenating the deprotected or reduced compound
-
Page/Page column 246-247

(2012/09/22)

AN IMPROVED PROCESS FOR THE PREPARATION OF CANDESARTAN CILEXETIL, POLYMORPHIC FORMS OF N-TRITYL CANDESARTAN AND THEIR USES THEREOF
The present invention provides an improved process for the preparation of candesartan cilexetil comprising the use of polymorphic Form A and Form B of N-trityl candesartan. Also, provided herein, new polymorphic Form A and Form B of N-trityl candesartan and the processes for their preparation.
-
Page/Page column 15-17

(2011/08/21)

PROCESS FOR THE PREPARATION OF CANDESARTAN CILEXETIL
The present invention provides an improved process for the preparation of candesartan and pharmaceutically acceptable salts and esters thereof for use in the treatment of hypertension and related diseases. Specifically, it refers to the deprotection of tetrazolyl -protecting group of candesartan or its derivative in the presence of iodine in one or more alcoholic solvents.
-
Page/Page column 8-9

(2011/07/30)

PROCESS FOR PREPARATION OF CANDESART AN CILEXETIL SUBSTANTIALLY FREE OF DES-CANDESARTAN CILEXETIL IMPURITY
The present invention provides a process for preparation of candeartan cilexetil substantially free of 2,3-dihydro-2-oxo-3-[[2'-(2H-tetrazol-5-yl)[l,l-biphenyl]-4- yl]methyl]-l-[[(cyclohexyloxy)carbonyl]oxy]ethylester-lH-benzimidazole-7- carboxylate (des-candesartan cilexetil) impurity.
-
Page/Page column 8-9

(2011/12/04)

METHOD OF REMOVING THE TRIPHENYLMETHANE PROTECTION GROUP
The present invention relates to a method of removing triphenylmethane protection group. The method for preparing biphenyl benzoic acid derivatives of the present invention is economically advantageous and very excellent in the aspect of improving process in that: process safety is secured by using acidic ion exchange resin in the presence of organic solvent instead of using highly corrosive acid; the reaction takes much less time than do the conventional reactions which use only anhydrous methanol and few sub-reaction does occur; and the ion-exchange resin of the present invention is excellent for mass-processing because the resin can be collected and recycled only by filtration after being used.
-
Page/Page column 14-15

(2010/07/02)

A noveland practical synthesis of substituted 2-ethoxy benzimidazole: Candesartan cilexetil
A novel and practical synthetic route for the preparation of candesartan cilexetil from methyl 2-amino-3-nitrobenzoate is described.The key steps are the reaction of methyl 2-bromo-3-(diethoxy-methyleneamino)benzoate with (2-(1-trityl-1H-tetrazol-5-yl) biphenyl-4-yl) methanamine and the final formation of 2-ethoxy benzimidazole ring via intramolecular N-arylation.The final ring closure process could be utilized to prepare other 2-substituted benzimidazoles.The method is simple for operation and suitable for industrial production.
Wang, Ping,Zheng, Guo-Jun,Wang, Ya-Ping,Wang, Xiang-Jing,Li, Yan,Xiang, Wen-Sheng
experimental part
p. 5402 - 5406
(2010/08/19)

PROCESS FOR THE PREPARATION OF CANDESARTAN CILEXETIL
The present invention relates to an improved process for the preparation of tritylated candesartan acid of formula (I) comprising a step of, reacting candesartan acid of formula (II) with trityl chloride in the presence of a base in a ketonic solvent.
-
Page/Page column 6

(2010/08/22)

Novel and practical synthesis of candesartan cilexetil
A novel and convergent synthetic route of candesartan cilexetil (API of Atacand), an effective angiotensin II receptor blocker, is described. Cleavage of the N-Boc and N-trityl protective group are implemented simultaneously and formation of the benzimidazole ring is conducted at the last step of this route, which gives candesartan cilexetil in 55% yield over six steps with 99.1% purity (HPLC).
Mao, Yongjun,Xiong, Ruisheng,Liu, Zheng,Li, Haihong,Shen, Jingkang,Shen, Jingshan
experimental part
p. 1503 - 1508
(2010/12/24)

Process for the preparation of tetrazolyl compounds
The invention provides a method for preparing candesartan cilexetil and related tetrazolyl compounds. More particularly, the invention relates to the preparation of candesartan cilexetil and related tetrazolyl compounds and includes a method of removing a protective group (e.g., triphenylmethane (trityl) protecting group) from an N-protected tetrazolyl compound using a Lewis acid in an inert solvent and in the presence of an alcohol (e.g., reacting an N-protected tetrazolyl compound with ZnCl2 in the presence of an alcohol).
-
Page/Page column 5-6

(2009/10/06)

AN IMPROVED PROCESS FOR THE PREPARATION OF CANDESARTAN CILEXETIL
The present invention relates to an improved process for the preparation of tritylated candesartan acid of formula (I) comprising a step of, reacting candesartan acid of formula (II) with trityl chloride in the presence of a base in a ketonic solvent.
-
Page/Page column 15

(2009/03/07)

Identification, synthesis and structural determination of some impurities of candesartan cilexetil
All principal candesartan cilexetil impurities and/or degradation products were synthesized and identified. The differentiation of N-l and N-2 ethylated candesartan cilexetil derivatives was performed using ID and 2D NMR experiments. The influence of the magnetic field on the resolution and sensitivity of NMR experiments is shown. Selective hydrolysis of these compounds then provided corresponding producrs of hydrolysis of the ethoxy group. Institute of Organic Chemistry and Biochemistry.
Havllcek, Jaroslav,Mandelova, Zuzana,Weisemann, Ruediger,Strelec, Ivo,Placek, Lukas,Radl, Stanislav
experimental part
p. 347 - 362
(2009/06/28)

PROCESS FOR PREPARATION OF CANDESARTAN CILEXETIL
There was provided a process for preparing candesartan cilexetil, the said process comprises hydrogenating a solution of trityl candesartan cilexetil in an alcohol with hydrogen in the presence of a palladium catalyst. Mixture of toluene and methanol was added to 1-(Cyclohexyloxy carbonyloxy)ethyl-2-ethoxy-1-[[2'-(N-triphenylmethyltetrazole-5-yl)biphenyl-4-yl] methyl]benzimidazole-7-carboxylate and hydrogenated at room temperature with hydrogen at atmospheric pressure in the presence of palladium on carbon until the hydrogen uptake was ceased. Filtered over celite bed, washed the bed with a mixture of toluene and methanol, filtrate was collected and concentrated. Co- distilled with acetonitrile, acetonitrile was added, stirred at room temperature, cooled to 0°C. stirred, filtered, washed with chilled acetonitrile and dried to get candesartan cilexetil.
-
Page/Page column 5

(2010/01/30)

Unusual detritylation of tritylated tetrazole in Sartan molecules
Tritylated tetrazole of 2a underwent unusual detritylation under basic reaction condition during the synthesis of methyl ether of olmesartan medoxomil 1. The unusual detritylation was found to be a common feature in the case of all tetrazole containing Sartan molecules (3-7).
Srimurugan, Sankareswaran,Suresh, Paulsamy,Babu, Balaji,Hiriyanna, Salmara Ganeshbhat,Pati, Hari Narayan
p. 383 - 384
(2008/09/20)

CRYSTALLINE 1-(CYCLOHEXYLOXYCARBONYLOXY) ETHYL 1-((2'-CYANOBIPHENYL-4-YL)METHYL)-2-ETHOXY-1H-BENZO[D]IMIDAZOLE-7-CARBOXYLATE AND A PROCESS FOR ITS PREPARATION
The present invention relates to 1-(cyclohexyloxycarbonyloxy)ethyl 1-((2'-cyanobiphenyl-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate in crystalline form and a process for its preparation, which is useful intermediate in the preparation of candesartan cilexetil. The present invention also relates to the preparation of candesartan cilexetil and pharmaceutical composition comprising candesartan cilexetil.
-
Page/Page column 28

(2008/12/08)

PROCESS FOR THE PREPARATION OF AMORPHOUS AND CRYSTALLINE FORMS OF CANDESARTAN CILEXETIL USING COLUMN CHROMATOGRAPHY
The present invention provides processes for the preparation of amorphous and crystalline candesartan cilexetil with quality that complies to Ph.Eur./ICH Guidelines by an economical way using easy accessible substances and pure starting compounds.
-
Page/Page column 21

(2008/06/13)

AN IMPROVED PROCESS FOR THE PREPARATION OF CANDESARTAN CILEXETIL
The invention relates to process for the preparation of Candesartan cilexetil. More particularly, it relates to the preparation of pure candesartan cilexetil by the deprotection of Trityl candesartan cilexetil with inorganic acids.
-
Page/Page column 6-7

(2008/06/13)

PROCESS FOR THE PREPARATION OF CANDESARTAN CILEXETIL
The present invention provides an improved synthesis for the manufacture of candesartan and pharmaceutically acceptable salts and esters thereof as active ingredients of a medicament for the treatment of hypertension and related diseases and conditions which comprises the removal of the tetrazolyl protecting group in an organic solvent, and in the presence of a Lewis acid.
-
Page/Page column 18

(2008/06/13)

A METHOD OF REMOVING THE TRIPHENYLMETHANE PROTECTING GROUP FROM PRECURSORS OF ANTIHYPERTENSIVE DRUGS
A method of removing the triphenylmethane protecting group from precursors of antihypertensive drugs of general formula I, wherein R is a metabolically degradable group, B is a heterocyclic moiety with one or two 5- or 6-membered rings at least one of which contains two nitrogen heteroatoms, in which the compound of formula I is reacted with water in the presence of a solvent which is partially or completely miscible with water.
-
Page/Page column 13; 14; 15

(2008/06/13)

METHOD FOR PRODUCTION OF CANDESARTAN
The invention relates to novel methods for the production of Candesartan, or a protected form of Candesartan, a Candesartan salt or ester, compounds of application in said method, methods for production thereof, use thereof in said method, a novel polymorph of Candesartan cilexetil, a method for production and use thereof for production of a medicament.
-
Page/Page column 28-29

(2010/11/08)

PROCESS FOR THE SYNTHESIS OF TETRAZOLES
A process for the synthesis of tetrazol derivative has been developed which starts from a tetrazole derivative where acidic hydrogen atom has been replaced by a protecting group and the deprotection is performed with a catalytic amount of organic acid and can proceed in an aqueous solvent.
-
Page/Page column 11-12

(2008/06/13)

PREPARATION OF CRUDE CANDESARTAN CILEXETIL
A process for preparing candesartan cilexetil comprising heating a solution of trityl candesartan cilexetil in a water immiscible solvent in the presence of at least one C1-C4 alcohol and a first portion of water; combining the solution with a second portion of water to obtain a two-phase system; and recovering candesartan cilexetil.
-
Page/Page column 5-6

(2008/06/13)

METHOD FOR OBTAINING BENZIMIDAZOLE DERIVATIVES AND INTERMEDIATES THEREOF
The present invention relates to a method for obtaining benzimizadole derivatives and intermediates thereof, preferably, for obtaining Candesartan and Candesartan cilexetil. Said method allows the benzimizadole derivatives to be obtained with a higher yield.
-
Page/Page column 21-22

(2010/11/25)

Novel polymorph forms of candesartan cilexetil
New crystalline forms of candesartan cilexetil is prepared from the solution in a chlorinated solvent by addition of an alkane while new amorphous is prepared from above solution by precipitating by addition of cycloalkane. The form depends on the concentration of a solute in a chlorinated solvent.
-
Page/Page column 8

(2008/06/13)

STABLE MICRONIZED CANDESARTAN CILEXETIL AND METHODS FOR PREPARING THEREOF
The invention encompasses sable candesartan cilexetil of fine particle size, wherein desethyl-candesartan (desethyl-CNS) within the stable candesartan cilexetil does not increase to more than about 0.1%w/w by HPLC relative to the initial amount of candesartan cilexetil, when the stable candesartan cilexetil is maintained at a temperature of about 550°C for at least 2 weeks, methods of making the same and pharmaceutical compositions thereof.
-
Page/Page column 11

(2008/06/13)

PROCESS FOR PREPARING CANDESARTAN CILEXETIL
A process for preparing candesartan cilexetil.
-
Page/Page column 17-18

(2010/10/19)

PREPARATION OF CANDESARTAN CILEXETIL
The invention encompasses processes for the synthesis of cilexetil trityl candesartan from the reaction of trityl candesartan with cilexetil halide in the presence of a base and a low boiling organic solvent. Optionally, the reaction may be conducted in the presence of a phase transfer catalyst.
-
Page/Page column 14

(2008/06/13)

PROCESS FOR PRODUCTION OF TETRAZOLYL COMPOUNDS
The present invention relates to processes for the production of tetrazolyl compounds including removing protective groups from an N-protected tetrazolyl compound with organic acids, giving a high yield of the tetrazolyl compound. The compounds produced in accordance with the processes provided can be useful as therapeutic aspects for hypertension, circulatory diseases, such as heart failure, strokes, cerebral apoplexy, nephropathy and nephritis.
-
Page/Page column 13-14

(2008/06/13)

Production method of aminobenzene compound
The present invention is to provide an industrially useful production method of an aminobenzene compound represented by the formula: which is characterized by reacting a mixture of a mono-halogeno compound represented by the formula: and di-halogeno compound represented by the formula: with a compound of the formula:
-
(2008/06/13)

Process for the production of tetrazolyl compounds
Disclosed is a method for removing a protective group of an N-protected tetrazolyl compound which comprises reacting said N-protected tetrazolyl compound with a mineral acid under substantially anhydrous conditions in the presence of an alcohol, insuring a high reaction yield of the object tetrazolyl compound.
-
(2008/06/13)

1-(CYCLOHEXYLOXYCARBONYLOXY)ETHYL 2-ETHOXY-1-[[2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL]METHYL]BENZIMIDAZOLE-7-CARBOXYLATE AND COMPOSITIONS AND METHODS OF PHARMACEUTICAL USE THEREOF
1-(Cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1 H-tetrazol-5-y l)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate or a pharmaceutically acceptable salt thereof has potent angiotensin II antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.
-
(2008/06/13)

Chemical Properties

Appearance/Colour :White crystalline powder
Melting Point: 168-170?C
Boiling Point: 843.3 ºC at 760 mmHg
Flash Point:463.8 ºC
Density: 1.37 g/cm³
Solubility:DMSO: ≥15mg/mL
Storage Temp.:-20°C Freezer
Refractive Index: 1.665
PKA: pKa 3.55 (H2O t=25.0 I=0.025) (Uncertain);5.91(H2O t=25.0 I=0.025) (Uncertain)
Merck: 14,1739
PSA: 143.34000
LogP: 6.31910

Global suppliers and manufacturers of 145040-37-5total 272 suppliers on LookChem

Company Name
Business Type
Min Order
FOB Price
Main Products
Contact

Hubei Lidu New Material Technology Co., Ltd
Business Type:Lab/Research institutions
Min Order:1 Kilogram
FOB Price:No Data
Main Products:62
Country:

Hubei Yuanmeng Biological Technology Co., Ltd.
Business Type:Trading Company
Min Order:1 Kilogram
FOB Price:USD $ 3.0-5.0 / Kilogram
Main Products:43
Country:

Dayang Chem (Hangzhou) Co.,Ltd.
Business Type:Lab/Research institutions
Min Order:1 Kilogram
FOB Price:USD $ 3.0-3.0 / Kilogram
Main Products:994
Country:

Sinoway Industrial Co., Ltd.
Business Type:Trading Company
Min Order:1 Kilogram
FOB Price:No Data
Main Products:105
Country:

Simagchem Corporation
Business Type:Manufacturers
Min Order:No Data
FOB Price:No Data
Main Products:110
Country:

Hangzhou Dingyan Chem Co., Ltd
Business Type:Trading Company
Min Order:1 Gram
FOB Price:USD $ 100.0-500.0 / Gram
Main Products:95
Country:

Hebei yanxi chemical co.,LTD.
Business Type:Manufacturers
Min Order:1 Metric Ton
FOB Price:USD $ 1.0-3.0 / Metric Ton
Main Products:84
Country:

Wuhan Fortuna Chemical Co.,Ltd
Business Type:Trading Company
Min Order:1 Kilogram
FOB Price:USD $ 800.0-900.0 / Kilogram
Main Products:51
Country:

Hefei TNJ chemical industry co.,ltd
Business Type:Trading Company
Min Order:1 Kilogram
FOB Price:No Data
Main Products:56
Country:

Hangzhou Think Chemical Co. Ltd
Business Type:Other
Min Order:1 Kilogram
FOB Price:No Data
Main Products:164
Country:

Ality Chemical Corporation
Business Type:Other
Min Order:1
FOB Price:No Data
Main Products:165
Country:

Xi'an Xszo Chem Co., Ltd.
Business Type:Manufacturers
Min Order:1 Gram
FOB Price:USD $ 0.1-0.1 / Gram
Main Products:108
Country:

Enke Pharma-tech Co.,Ltd. （Cangzhou, China ）
Business Type:Manufacturers
Min Order:1 Kilogram
FOB Price:USD $ 1.0-1.0 / Kilogram
Main Products:53
Country:

Xi`an Eastling Biotech Co., Ltd.
Business Type:Lab/Research institutions
Min Order:1 Gram
FOB Price:USD $ 8.0-9.0 / Gram
Main Products:21
Country:

Shandong Jiulong Hisince Pharmaceutical Co.,Ltd.
Business Type:Manufacturers
Min Order:1 Kilogram
FOB Price:No Data
Main Products:29
Country:

COLORCOM LTD.
Business Type:Manufacturers
Min Order:1 Metric Ton
FOB Price:No Data
Main Products:32
Country:

Chemwill Asia Co., Ltd.
Business Type:Manufacturers
Min Order:5 Kiloliter
FOB Price:USD $ 1.2-5.0 / Kiloliter
Main Products:56
Country:

Kono Chem Co.,Ltd
Business Type:Other
Min Order:1 Kilogram
FOB Price:USD $ 450.0-500.0 / Kilogram
Main Products:86
Country:

Hubei DiBo chemical co., LTD
Business Type:Other
Min Order:25 Metric Ton
FOB Price:USD $ 2.0-3.0 / Metric Ton
Main Products:34
Country:

LIDE PHARMACEUTICALS LIMITED
Business Type:Lab/Research institutions
Min Order:1 Kilogram
FOB Price:USD $ 0.9-1.0 / Kilogram
Main Products:56
Country:

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 145040-37-5

Article Database

145040-37-5

Articles about 145040-37-5Total 41 be found

More Articles about upstream products of 145040-37-5

More Articles about downstream products of 145040-37-5

Chemical Properties

Appearance/Colour :White crystalline powder

Melting Point: 168-170?C

Boiling Point: 843.3 ºC at 760 mmHg

Flash Point:463.8 ºC

Density: 1.37 g/cm³

Solubility:DMSO: ≥15mg/mL

Storage Temp.:-20°C Freezer

Refractive Index: 1.665

PKA: pKa 3.55 (H2O t=25.0 I=0.025) (Uncertain);5.91(H2O t=25.0 I=0.025) (Uncertain)

Merck: 14,1739

PSA: 143.34000

LogP: 6.31910

Global suppliers and manufacturers of 145040-37-5total 272 suppliers on LookChem

Article Database

145040-37-5

Articles about 145040-37-5Total 41 be found

More Articles about upstream products of 145040-37-5

More Articles about downstream products of 145040-37-5

Chemical Properties

Appearance/Colour :White crystalline powder

Melting Point: 168-170?C

Boiling Point: 843.3 ºC at 760 mmHg

Flash Point:463.8 ºC

Density: 1.37 g/cm3

Solubility:DMSO: ≥15mg/mL

Storage Temp.:-20°C Freezer

Refractive Index: 1.665

PKA: pKa 3.55 (H2O t=25.0 I=0.025) (Uncertain);5.91(H2O t=25.0 I=0.025) (Uncertain)

Merck: 14,1739

PSA: 143.34000

LogP: 6.31910

Global suppliers and manufacturers of 145040-37-5total 272 suppliers on LookChem

Density: 1.37 g/cm³